Ra Capital Management, L.P. C4 Therapeutics, Inc. Transaction History
Ra Capital Management, L.P.
- $6.17 Billion
- Q4 2024
A detailed history of Ra Capital Management, L.P. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 4,878,000 shares of CCCC stock, worth $14.7 Million. This represents 0.28% of its overall portfolio holdings.
Number of Shares
4,878,000
Previous 4,878,000
-0.0%
Holding current value
$14.7 Million
Previous $27.8 Million
36.84%
% of portfolio
0.28%
Previous 0.39%
Shares
4 transactions
Others Institutions Holding CCCC
# of Institutions
126Shares Held
63MCall Options Held
651KPut Options Held
115K-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$21 Million1.75% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.85MShares$20.6 Million9.58% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.07MShares$18.3 Million0.11% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$13.7 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.38MShares$13.2 Million0.43% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $147M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...